Plain-English guides to money, tech, health, home and everyday life.
The FDA is requiring a new warning on Ozempic, Wegovy, Mounjaro, Zepbound and all GLP-1 drugs over a rare eye condition that can cause sudden vision loss. Here’s who is affected and what to do.
Liafi Studio Editors
The U.S. Food and Drug Administration is requiring a new safety warning on all GLP-1 drugs, the class that includes Ozempic, Wegovy, Mounjaro and Zepbound, because of a potential increased risk of a rare eye condition that can cause sudden, painless vision loss in one eye. The agency’s drug safety communication, dated Nov. 9, 2026, says the condition is non-arteritic anterior ischemic optic neuropathy, or NAION, and that it can include permanent vision loss.
The warning will be added to the Warnings and Precautions section of the prescribing information for every GLP-1 receptor agonist. The FDA is not telling people to stop these medicines on their own. Here’s what the agency found, which drugs are included, which symptoms to watch for, and when to call a doctor.
NAION happens when blood flow drops to the front of the optic nerve, the part known as the optic disc. The FDA says the underlying cause is not completely understood. It can cause acute, painless decreased vision in one eye. If it happens in one eye, the risk is higher that it will happen in the other eye later.
Symptoms the FDA lists include:
The agency tells patients to contact their health care professional right away if any of those symptoms appear. If NAION is suspected, doctors are told to refer the patient promptly to an ophthalmologist. If someone has already had a NAION event, they should talk with their clinician about whether to keep taking the GLP-1 drug or stop it.
Known risk factors can overlap with the reasons people are prescribed these drugs in the first place, including diabetes, high blood pressure, sleep apnea, smoking, anemia and kidney disease. That overlap is one reason the reports were hard to interpret on their own.
The labeling change applies to the entire GLP-1 receptor agonist class, not one brand. The FDA’s list of approved products is:
These medicines are widely used for type 2 diabetes and for long-term weight management. Some are also approved to lower the risk of major cardiovascular events, to slow worsening kidney disease in certain patients, to treat moderate to severe obstructive sleep apnea in adults with obesity, or to treat metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver scarring.
The review started after a July 2024 study in JAMA Ophthalmology raised questions about NAION in people prescribed semaglutide. The FDA says that study had limitations, but it was enough to prompt a broader look at clinical trials, animal data, case reports and observational studies.
In a meta-analysis of 126 randomized, controlled trials covering 134,253 patients, the agency found 15 probable NAION events: 10 in people on a GLP-1 drug, 5 in people on a placebo, and none in people on another non-GLP-1 diabetes drug. That works out to 6.4 cases per 100,000 person-years with GLP-1 drugs, compared with 3.8 cases per 100,000 person-years in the comparison group. In the general population of adults over 50, published NAION rates are about 2.3 to 10.2 cases per 100,000 people per year.
A separate FDA study in its Sentinel real-world data network compared adults with type 2 diabetes who started a GLP-1 drug with those who started other common diabetes medicines. There was no statistically significant increase compared with SGLT-2 inhibitors. There was a higher risk compared with DPP-4 inhibitors (hazard ratio 1.43). Methodologically rigorous published studies, the FDA said, generally pointed in the same direction.
Animal studies did not identify a mechanism. Even so, NAION cases have been reported for all currently marketed GLP-1 products, and the agency concluded there is a potential increased risk of this rare event. That is why the warning is being added to the whole class. NBC News and The Washington Post also reported the decision on Nov. 9–10.
If you take one of these medicines and feel fine, the FDA is not asking you to stop it on your own. It is asking you to know the symptoms and to get help quickly if vision in one eye suddenly changes.
A primary care clinician or nurse practitioner is often the first person to sort this out, which is why it helps to have a regular relationship with one. Our guide to how to choose the right primary care provider covers what to look for if you don’t already have one.
Family members who help with prescriptions should know the warning too. November is National Family Caregivers Month, and our guide to this year’s theme, stats and how to help includes practical ways to support someone who is managing new medication advice.
This warning does not change the fact that GLP-1 drugs have other approved uses, including weight and metabolic care. People comparing medical weight-loss options, including surgery, can also look at our explainer on bariatric surgery revision costs, insurance and financing, which is a different path with its own risks and coverage questions.
No. The FDA is warning about a potential increased risk of a rare condition, NAION, that can cause sudden vision loss in one eye, sometimes permanently. Most people who take these drugs will never have it. The trial analysis found 6.4 cases per 100,000 person-years on the drugs, versus 3.8 in the comparison group.
Not on your own, unless your clinician tells you to. If you develop symptoms of NAION, contact a health care professional right away. If you have already had NAION, discuss whether to continue.
Yes. The FDA included tirzepatide products even though they also act on the GIP receptor, because they are GLP-1 receptor agonists as well.
Yes. Orforglipron, sold as Foundayo and approved in 2026, is on the FDA’s list.
It is uncommon. In the FDA’s trial analysis, the rate was still measured in cases per 100,000 person-years, which is in the same broad range reported in adults over 50 in the general population.
This article is for general information, not medical advice. Talk with a licensed clinician about your own prescription. Source: FDA Drug Safety Communication, Nov. 9, 2026; NBC News; The Washington Post.
Featured image: Main entrance of FDA Building 51 on the White Oak campus, photo by the U.S. Food and Drug Administration, public domain, via Wikimedia Commons (cropped).
Liafi Studio is an independent magazine of useful, plain-English guides: money and work, tech, health, home, learning, style and family life.
© 2026 Liafi Studio. All rights reserved.
Liafi Studio is ad-supported and some posts contain sponsored links, always labelled. Our guides are general information, not professional, medical, legal or financial advice.
